Lan Yuan

Dr. Lan Yuan


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
ZHZhongyu Han
Zhongyu Han
QLQiong Liu
Qiong Liu
HLHongpeng Li
Hongpeng Li
MZMeiqi Zhang
Meiqi Zhang
LYLuling You
Luling You
HCHaoran Chen
Haoran Chen
Cardiovascular and cerebrovascular diseases are the number one killer threatening people's life and health, among which cardiovascular thrombotic events are the most common. As the cause of particularly serious cardiovascular events, thrombosis can trigger fatal crises such as acute coronary syndrome (myocardial infarction and unstable angina), cerebral infarction and so on. Circulating monocytes are an important part of innate immunity. Their main physiological functions are phagocytosis, removal of injured and senescent cells and their debris, and development into macrophages and dendritic cells. At the same time, they also participate in the pathophysiological processes of pro-coagulation and anticoagulation. According to recent studies, monocytes have been found to play a significant role in thrombosis and thrombotic diseases of the immune system. In this manuscript, we review the relationship between monocyte subsets and cardiovascular thrombotic events and analyze the role of monocytes in arterial thrombosis and their involvement in intravenous thrombolysis. Finally, we summarize the mechanism and therapeutic regimen of monocyte and thrombosis in hypertension, antiphospholipid syndrome, atherosclerosis, rheumatic heart disease, lower extremity deep venous thrombosis, and diabetic nephropathy.

8 March 2024 in Kidney Diseases
Verified
Journal Article
Open access
PDF file
ZHZhongyu Han
Zhongyu Han
YLYuanke Luo
Yuanke Luo
HCHaoran Chen
Haoran Chen
GZGuochen Zhang
Guochen Zhang
LYLuling You
Luling You
SZShiyi Zhou
Shiyi Zhou
Background: Ferroptosis, a newly recognized form of programmed cell death, is distinguished by its reliance on reactive oxygen species and iron-mediated lipid peroxidation, setting it apart from established types like apoptosis, cell necrosis, and autophagy. Recent studies suggest its role in exacerbating or mitigating diseases by influencing metabolic and signaling pathways in conditions such as tumors and ischemic organ damage. Evidence also links ferroptosis to various kidney diseases, prompting a review of its research status and potential breakthroughs in understanding and treating these conditions. Summary: In acute kidney disease (AKI), ferroptosis has been confirmed in animal kidneys after being induced by various factors such as renal ischemia-reperfusion and cisplatin, and glutathione peroxidase 4 (GPX4) is linked with AKI. Ferroptosis is associated with renal fibrosis in chronic kidney disease (CKD), TGF-β1 being crucial in this regard. In diabetic nephropathy (DN), high SLC7A11 and low nuclear receptor coactivator 4 (NCOA4) expressions are linked to disease progression. For polycystic kidney disease (PKD), ferroptosis promotes the disease by regulating ferroptosis in kidney tissue. Renal cell carcinoma (RCC) and lupus nephritis (LN) also have links to ferroptosis, with mtDNA and iron accumulation causing RCC and oxidative stress causing LN. Key Messages: Ferroptosis is a newly identified form of programmed cell death that is associated with various diseases. It targets metabolic and signaling pathways and has been linked to kidney diseases such as AKI, CKD, PKD, DN, LN, and clear cell RCC. Understanding its role in these diseases could lead to breakthroughs in their pathogenesis, etiology, and treatment.

1 December 2004 in Life Sciences
Verified
Journal Article
Closed access
HLHongmei Liu
Hongmei Liu
LYLan Yuan
Lan Yuan
SXShanjin Xu
Shanjin Xu
TZTianlan Zhang
Tianlan Zhang
Kui WangKui Wang
Kui Wang

18 October 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LHLi-Jun Huang
Li-Jun Huang
YZYong-Yuan Zhao
Yong-Yuan Zhao
LYLan Yuan
Lan Yuan
JMJi-Mei Min
Ji-Mei Min
LZLi-He Zhang
Li-He Zhang

1 July 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
YCYuxiang Chen
Yuxiang Chen
CLChi Liu
Chi Liu
SZShaomi Zhu
Shaomi Zhu
XLXin Liang
Xin Liang
QZQinxiu Zhang
Qinxiu Zhang
LSLinjiang Song
Linjiang Song

28 September 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
LYLuling You
Luling You
ZHZhongyu Han
Zhongyu Han
HCHaoran Chen
Haoran Chen
LCLiuyan Chen
Liuyan Chen
YLYumeng Lin
Yumeng Lin
LYLan Yuan
Lan Yuan
Chemical modifications are a specific and efficient way to regulate the function of biological macromolecules. Among them, RNA molecules exhibit a variety of modifications that play important regulatory roles in various biological processes. More than 170 modifications have been identified in RNA molecules, among which the most common internal modifications include N6-methyladenine (m6A), n1-methyladenosine (m1A), 5-methylcytosine (m5C), and 7-methylguanine nucleotide (m7G). The most widely affected RNA modification is m6A, whose writers, readers, and erasers all have regulatory effects on RNA localization, splicing, translation, and degradation. These functions, in turn, affect RNA functionality and disease development. RNA modifications, especially m6A, play a unique role in renal cell carcinoma disease. In this manuscript, we will focus on the biological roles of m6A in renal diseases such as acute kidney injury, chronic kidney disease, lupus nephritis, diabetic kidney disease, and renal cancer.